Navigating the complexities of dual CNV findings: a case of DEE7 caused by a de novo KCNQ2 deletion and a Co-occurring chromosome 13 duplication – a case report and literature review - Scorecard - MDSpire
Advertisement
Navigating the complexities of dual CNV findings: a case of DEE7 caused by a de novo KCNQ2 deletion and a Co-occurring chromosome 13 duplication – a case report and literature review
Clinical Scorecard: Exploring the Challenges of Dual CNV Results: A Case Study of DEE7 Linked to a De Novo KCNQ2 Deletion and Concurrent Chromosome 13 Duplication – A Case Report and Review of Existing Literature
At a Glance
Category
Detail
Condition
Developmental and Epileptic Encephalopathy 7 (DEE7)
Key Mechanisms
Caused by mutations in the KCNQ2 gene leading to haploinsufficiency and increased neuronal excitability.
Target Population
Infants with early-onset seizures and developmental delay.
Care Setting
Pediatric neurology and genetics.
Key Highlights
Case of a 1 year 5 months female with severe neonatal seizures and developmental delay.
Identified a de novo KCNQ2 large deletion and a chromosome 13 duplication.
Achieved complete seizure freedom and modest neurodevelopmental progress with early intervention.
Emphasizes the importance of CNV analysis in epilepsy genetic testing.
Highlights the potential for improved outcomes even in severe genotypes.
Guideline-Based Recommendations
Diagnosis
Utilize trio-based whole-exome sequencing for genetic diagnosis.
Incorporate CNV analysis in genetic testing protocols.
Management
Initiate early targeted pharmacological treatment for seizure control.
Monitor neurodevelopmental progress closely.
Monitoring & Follow-up
Regular follow-up assessments of seizure frequency and developmental milestones.
Risks
Potential for severe phenotypic manifestations associated with KCNQ2 deletions.
Patient & Prescribing Data
Infants diagnosed with DEE7 due to KCNQ2 mutations.
Early intervention can lead to significant improvements in seizure control and development.
Clinical Best Practices
Perform comprehensive genetic testing in cases of early-onset epilepsy.
Engage in multidisciplinary care involving neurology and genetics.
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
